Description

Nangibotide is a TREM-1 receptor inhibitor that can modulate innate immune response. Nangibotide can reduce systemic and in situ inflammatory reaction in rodent models of myocardial ischaemia‐reperfusion[1].—COVID-19-immunoregulation–C54H82N14O22S2—-[1]Cuvier V, et, al. A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. Br J Clin Pharmacol. 2018 Oct;84(10):2270-2279.–2014384-91-7–1343.44—-OC(C=C1)=CC=C1C[C@@H](C(NCC(N[C@@H](CS)C(N[C@H](C(N)=O)CCSC)=O)=O)=O)NC([C@H](CCC(O)=O)NC(CNC([C@H](C)NC([C@H](CC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(N)=O)NC([C@@H](N)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology–H2O–Others—-Others–Peptides